EGFR and gastric cancer: The top enriched pathways (with a strength of enrichment (SOE) of >1 and p < 0.05) included cell adherent junctions, EGFR tyrosine kinase inhibitor resistance, central carbon metabolism, CRC, pancreatic cancer, hepatocellular carcinoma, gastric cancer, and melanomas (Figure 4E), while enriched GOs (with a SOE of >1 and p < 0.05) included the c-MET, ERBB2, and EGFR signaling pathways, MAPKK activation, and negative regulation of cellular responses to drugs (Figure 4F).